J. Goldman & Co’s Abeona Therapeutics ABEO Stock Holding History

J. Goldman & Co’s Portfolio ABEO Stock Details ABEO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$2.87M	Buy	640,530 +241,614	+61%	+$1.21M	0.08%	263
2025 Q4	$2.1M	Buy	+398,916	New	+$2.01M	0.06%	308
2024 Q2	–	Sell	-22,750	Closed	-$165K	–	427
2024 Q1	$165K	Sell	22,750 -407,066	-95%	-$2.58M	0.01%	370
2023 Q4	$2.15M	Sell	429,816 -65,519	-13%	-$288K	0.09%	181
2023 Q3	$2.09M	Sell	495,335 -2,709	-0.5%	-$10.3K	0.07%	200
2023 Q2	$2.01M	Buy	+498,044	New	+$1.74M	0.07%	209
2018 Q2	–	Sell	-5,907	Closed	-$2.12M	–	347
2018 Q1	$2.12M	Sell	5,907 -364	-6%	-$135K	0.09%	207
2017 Q4	$2.48M	Buy	6,271 +5,343	+576%	+$2.21M	0.13%	178
2017 Q3	$396K	Sell	928 -11,272	-92%	-$3.03M	0.02%	279
2017 Q2	$1.95M	Buy	12,200 +824	+7%	+$112K	0.11%	181
2017 Q1	$1.42M	Buy	+11,376	New	+$1.47M	0.07%	232

Other funds holding ABEO

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACM

AIGH Capital Management Baltimore, Maryland $733M AUM 327.32% 1-Year Est. Return

CCC

Cable Car Capital San Francisco, California $289M AUM 26.33% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PBM

Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return

KCM

Kennedy Capital Management St Louis, Missouri $4.72B AUM 36.69% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

J. Goldman & Co's ABEO Position: Q1 2026 in Review

J. Goldman & Co increased its Abeona Therapeutics (ABEO) stake by 61% in Q1 2026, buying an estimated $1.21M and bringing the position to 640,530 shares worth $2.87M. The position accounts for 0.08% of the portfolio, ranked #263.

J. Goldman & Co first reported a position in ABEO in Q1 2017 and has held it in 11 quarters since. 108 funds tracked by Wall St. Rank hold ABEO as of Q1 2026.

J. Goldman & Co held 640,530 shares of Abeona Therapeutics worth $2.87M as of Q1 2026.
J. Goldman & Co bought 241,614 Abeona Therapeutics shares in Q1 2026, an estimated $1.21M.
Abeona Therapeutics made up 0.08% of J. Goldman & Co's portfolio in Q1 2026, its #263 holding.
J. Goldman & Co first reported a position in Abeona Therapeutics in Q1 2017 and has held it in 11 quarters since.
108 funds tracked by Wall St. Rank held Abeona Therapeutics as of Q1 2026.

Based on J. Goldman & Co's 13F filing for Q1 2026, filed 15 May 2026.